All In Biotech

Drug Trial Radar · NCT02038738

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Last checked: Nov 20, 2026Latest source record: Jan 17, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

250

Planned (sponsor's estimate)

Start

Mar 2014

Primary completion

Mar 2019

Sponsor

Lead sponsor
Ochsner Health SystemAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 17, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.

Conditions

  • Neuroendocrine
  • Neuroendocrine Tumor
  • Neuroendocrine Cancer
  • Neuroendocrine Carcinoma
  • Carcinoid
  • Carcinoid Tumor
  • Islet Cell Tumor
  • Apudoma

Interventions

  • 68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse Events as a Measure of Safety and TolerabilityTime frame: 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ochsner Medical Center - Kenner

    Kenner, Louisiana

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.